← Drug-vs-drug verdicts

CagriSema vs Zepbound (2026): Investigational Amylin+GLP-1 vs Approved GIP+GLP-1

CagriSema (cagrilintide + semaglutide, Novo Nordisk) vs Zepbound (tirzepatide, Eli Lilly)

Last verified November 2026

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

The verdict

CagriSema and Zepbound stand at the frontier of pharmacological weight loss, and they now have a direct comparison. In REDEFINE 4, an 84-week open-label phase 3 trial in 809 adults with obesity, CagriSema 2.4/2.4 mg produced 23.0% weight loss versus 25.5% with tirzepatide 15 mg if everyone stayed on treatment (20.2% vs 23.6% by the treatment-regimen estimand), and it did not meet its primary goal of showing non-inferiority to tirzepatide. Those are Novo Nordisk's February 2026 headline figures, not yet a journal paper. Across separate trials, REDEFINE-1 showed ~20.4% with CagriSema at 68 weeks (PMID 40544433), and our SURMOUNT-1 trial deep dive covers tirzepatide's up to ~20.9% at 72 weeks. The two use different dual mechanisms: CagriSema pairs an amylin receptor agonist (cagrilintide) with semaglutide, while Zepbound co-activates GIP and GLP-1 receptors. The practical difference is approval status: Zepbound has been FDA-approved since November 2023, while CagriSema is under FDA review after a December 2025 submission. For patients who want the most effective approved treatment, Zepbound is the answer; our REDEFINE trial results summary covers the rest of the CagriSema data.

Side-by-side comparison

FieldCagriSemaZepbound
Peak weight loss (vs placebo)~20.4% at 68 wk — REDEFINE-1 (PMID 40544433)Up to ~20.9% (15 mg arm) at 72 wk — SURMOUNT-1 (PMID 35658024)
Head-to-head dataREDEFINE 4 (Feb 2026 headline, open-label): −23.0% at 84 wk; non-inferiority to tirzepatide not met−25.5% at 84 wk with tirzepatide 15 mg in REDEFINE 4
Mechanism of actionAmylin receptor + GLP-1 receptor agonist (cagrilintide + semaglutide 2.4 mg)Dual GIP receptor + GLP-1 receptor agonist (tirzepatide)
FDA approval statusInvestigational; under FDA review after a Dec 2025 submissionFDA-approved for chronic weight management since November 2023
Cardiovascular outcomesNo completed CV outcomes trial; data pendingSURMOUNT-MMO trial ongoing; CV indication not yet approved
AdministrationOnce-weekly subcutaneous injection (investigational dosing)Once-weekly subcutaneous injection (2.5–15 mg, dose escalation)
Commercial availability & priceNot commercially available — clinical trials onlyAvailable by prescription; $299-$449/mo self-pay via LillyDirect (KwikPen or vials)

Frequently asked questions

Is CagriSema better than Zepbound for weight loss?

The one head-to-head trial favors Zepbound. In REDEFINE 4, an 84-week open-label phase 3 trial, CagriSema produced 23.0% weight loss versus 25.5% with tirzepatide 15 mg if everyone stayed on treatment, and it did not show non-inferiority to tirzepatide. These are Novo Nordisk headline results from February 2026, not yet published in a journal.

Which drug has a better mechanism — CagriSema or Zepbound?

They use distinct dual-receptor strategies. CagriSema activates amylin and GLP-1 receptors using two separate molecules; Zepbound activates GIP and GLP-1 receptors using a single molecule (tirzepatide). Both approaches outperform GLP-1 monotherapy. In the REDEFINE 4 head-to-head, CagriSema did not show non-inferiority to tirzepatide 15 mg on weight loss.

When will CagriSema be approved compared to Zepbound?

Zepbound received FDA approval in November 2023. Novo Nordisk submitted CagriSema to the FDA in December 2025 and says it expects a decision by late 2026; it was not approved anywhere as of late October 2026.

Could CagriSema help patients who stopped responding to Zepbound?

Possibly. Because CagriSema works through amylin receptor agonism rather than GIP receptor agonism, its mechanism is distinct from Zepbound's. A patient who has plateaued on Zepbound might respond differently to CagriSema's complementary pathway — but no clinical data on sequential use currently exist.

Do CagriSema and Zepbound have the same side effects?

Both produce GLP-1-class gastrointestinal side effects (nausea, vomiting, diarrhea, constipation). Zepbound's added GIP component and CagriSema's added amylin component each modulate satiety through different secondary pathways, so their tolerability profiles may differ in subtle ways. Novo Nordisk reported that GI events were the most common with CagriSema in REDEFINE 4, but the full side-by-side safety data have not been published.

What is the price difference between CagriSema and Zepbound?

CagriSema has no commercial price — it is not yet approved or sold. Zepbound (tirzepatide) costs $299-$449/mo self-pay through LillyDirect for the KwikPen or vials, depending on dose and refill timing (up to $699/mo at higher doses without timely refills).

References

  1. 1.Garvey WT, Blüher M, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) N Engl J Med. 2025;393(7):635-647. 2025. PMID: 40544433.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) N Engl J Med. 2022;387(3):205-216. 2022. PMID: 35658024.
  3. 3.Davies MJ, Bajaj HS, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) N Engl J Med. 2025;393(7):648-659. 2025. PMID: 40544432.
  4. 4.Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity Lancet Diabetes Endocrinol. 2026;14(6):450-462. 2026. PMID: 42009015.
  5. 5.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) N Engl J Med. 2021;384(11):989-1002. 2021. PMID: 33567185.
  6. 6.Novo Nordisk A/S CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved Novo Nordisk company announcement. 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916501

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.